Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer.

Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T, Liu R, Fan Q, Zhu K, Li J, Zhan Y, Ying G, Ba Y. · 2020

Read Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. by Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T, Liu R, Fan Q, Zhu K, Li J, Zhan Y, Ying G, Ba Y. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7053238.txt.

Introduction

Wang and co-authors trace how colorectal cancer cells pass on drug resistance in Molecular Oncology. Tumours rely on aerobic glycolysis for fast growth, and the enzyme PKM2 drives that process. Resistant cells in the team's tests carried more PKM2 and made more energy than sensitive ones. A circular RNA called ciRS-122 rose alongside resistance.

CiRS-122 works by soaking up miR-122, a small RNA that normally holds PKM2 down. Drug-resistant cells pack ciRS-122 into exosomes and ship it to nearby cells. Cells that receive it boost glycolysis and become drug resistant too. Blocking the circular RNA and sending that blocker in exosomes reversed the effect in animals, and oxaliplatin worked again. The chain from circular RNA to microRNA to enzyme shows how resistance spreads through a tumour with no new mutation, and names a target for stopping it.

Catalog record

CREATORWang X, Zhang H, Yang H, Bai M, Ning T, Deng T, Liu R, Fan Q, Zhu K, Li J, Zhan Y, Ying G, Ba Y.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7053238

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Exosome‐delivered circRNA promotes glycolysis to induce chemoresistance through the miR‐122‐PKM2 axis in colorectal cancer By Xinyi Wang, Haiyang Zhang, Haiou Yang, Ming Bai, Tao Ning, Ting Deng, Rui Liu, Qian Fan, Kegan Zhu, Jialu Li, Yang Zhan, Guoguang Ying Published in: Molecular Oncology DOI: 10.1002/1878-0261.12629 ABSTRACT Malignant tumors, including colorectal cancer (CRC), usually rely on ATP generation through aerobic glycolysis for both rapid growth and chemotherapy resistance. The M2 isoform of pyruvate kinase (PKM2) has a key role in catalyzing glycolysis, and PKM2 expression varies even within a single tumor. In this study, we confirmed that expression of PKM2 is heterogeneous in CRC cells, namely high in oxaliplatin‐resistant cells but relatively low in sensitive cells, and found that chemoresistant cells had enhanced glycolysis and ATP production. In addition, we report a PKM2‐dependent mechanism through which chemosensitive cells may gradually transform into chemoresistant cells. The circular RNA hsa_circ_0005963 (termed ciRS‐122 in this study), which was determined to be a sponge for the PKM2‐targeting miR‐122, was positively correlated with chemoresistance. In vitro and in vivo studies showed that exosomes from oxaliplatin‐resistant cells delivered ciRS‐122 to sensitive cells, thereby promoting glycolysis and drug resistance through miR‐122 sponging and PKM2 upregulation. Moreover, si‐ciRS‐122 transported by exosomes could suppress glycolysis and reverse resistance to oxaliplatin by regulating the ciRS‐122–miR‐122–PKM2 pathway in vivo. Exosomes derived from chemoresistant CRC cells could transfer ciRS‐122 across cells and promote glycolysis to reduce drug susceptibility in chemosensitive cells. This intercellular signal delivery suggests a potential novel therapeutic target and establishes a foundation for future clinical applications in drug‐resistant CRC. AbbreviationsAabsorbanceABCATP‐binding cassetteCG control groupcircRNAcircular RNAciRS‐122hsa_circ_0005963 was a sponge for miR‐122 and named ciRS‐122 in the studyCRCcolorectal cancerCtcycle thresholdEG experimental groupIHCimmunohistochemistrylncRNAlong non‐coding RNAL‐OHP oxaliplatinmiRNA microRNANC negative controlNTAnanoparticle tracking analysisPI propidium iodide PKM2M2 isoform of pyruvate kinaseRTroom temperaturesiRNA short interfering RNATEMtransmission electron microscopyWBwestern blot INTRODUCTION Malignant solid tumors take up large amounts of glucose to produce lactate even in the presence of oxygen compared with what is observed in the surrounding tissue; this phenomenon has been termed ‘aerobic glycolysis’ (Liberti and Locasale, 2016). A key control for metabolizing glucose by either glycolysis or the oxidative phosphorylation process is regulation of the flux of glycolysis. Pyruvate kinase catalyzes the final reaction in glycolysis by transferring the high‐energy phosphate from phosphoenolpyruvate to ADP to produce ATP and pyruvate. Among the four isoforms of pyruvate kinase, the M2 isoform (PKM2) is the dominant type in proliferating and cancer cells (Wong et al., 2015). Known as heterogeneity, clonal variation and microenvironmental influence on cancer cells result in distinct populations of cells, even within a single tumor (Prasetyanti and Medema, 2017). The glycolytic phenotypes do not display homogeneously in tumors because of the diverse expression of PKM2. When PKM2 is overexpressed, the glycolytic rate is high, and most glucose is converted to lactate with a rapid production of ATP (Chaneton and Gottlieb, 2012). Multiple biological activities within cells require the consumption of ATP. In cancer cells, some ATP‐binding cassette (ABC) drug efflux pumps embedded across the membranes play a pivotal role in survival (Li et al., 2016). With increasing intracellular ATP, the transporters could obtain more energy to pump the drugs out of the cells to prevent intracellular drugs from accumulating and damaging the cells. In an individual or even a single tumor, the capability of ATP generation varies among distinct sets of cells due to the diversity of glycolysis rates; hence, the ability to reduce drugs in the cytoplasm could be different (Zhou et al., 2012). In other words, drug‐sensitive cells and drug‐resistant cells might exist simultaneously within the same tumor. Nevertheless, the development of the ABC transporter as a therapeutic target has been unsuccessful in 30 years of research (Robey et al., 2018). Chemoresistance remains a continuing challenge in the field of cancer therapy. It remains unclear how drug‐sensitive cells become drug‐resistant ones as a tumor progresses in an individual. Exosomes have been noted as carriers for intercellular signal transduction in recent years (Zhang et al., 2017). Exosomes are extracellular vesicles secreted by various cells, with diameters ranging from 30 to 100 nm, delivering micro (mi)RNA, long non‐coding (lnc)RNA, circular (circ)RNA and proteins (Mathieu et al., 2019; Xu et al., 2018). It was demonstrated that some horizontal interactions via exosomes modulated drug response in a heterogeneous tumor in vivo. Drug‐resistant and ‐sensitive clones coexisted initially, but most cells eventually became poorly responsive to chemotherapy (Sharma, 2017). Among the various cargos carried in exosomes, circRNA are a novel class of noncoding RNA that are exceptionally stable. Some circRNA have been shown to function as efficient micro (mi)RNA sponges with gene‐regulatory potential involved in cancer (Kristensen et al., 2018). Research examining circRNA is steadily increasing and is predominantly about intracellular signal transduction but largely has not investigated intercellular regulation (Arnaiz et al., 2018). The current study is designed to research the mechanism of drug resistance in colorectal cancer (CRC). The expression pattern of PKM2 was heterogeneous even within a single tumor, being high in drug‐resistant cells but relatively low in drug‐sensitive cells. Glycolysis was also stronger in drug‐resistant cells, with more ATP production being observed. A panel of circRNA was found to be dysregulated; among these circRNA, ciRS‐122 was predicted to act as a sponge of miR‐122 in oxaliplatin‐resistant CRC cells. Subsequently, it was verified that the expression level of ciRS‐122 in serum exosomes was positively correlated with chemoresistance. An in vitro and in vivo study demonstrated that exosomes from drug‐resistant cells could deliver ciRS‐122 to drug‐sensitive cells, in which glycolysis and drug resistance were enhanced by decreasing miR‐122 and upregulating PKM2. In addition, the inhibition of ciRS‐122 suppressed glycolysis and reversed the resistance to oxaliplatin in CRC. The results of this study indicate that exosomes play a key role in mediating chemoresistance from drug‐resistant cells to drug‐sensitive cells by delivering circRNA, and circRNA serve as a potentially novel target for the treatment of drug‐resistant CRC. MATERIALS AND METHODS Human tissue and immunohistochemistry All human CRC tissue samples were obtained from Tianjin Medical University Cancer Institute and Hospital. The tumors were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and then stained with anti‐PKM2 antibodies (Santa Cruz, CA, USA). The experiments were undertaken with the understanding and written consent of each subject. The study methodologies conformed to the standards set by the Declaration of Helsinki, and the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital approved all aspects of this study. Animals Female nude mice (BALB/c‐nu, 4 weeks) purchased from GemPharmatech Co., Ltd (Jiangsu, China) were fed in a special pathogen‐free animal facility and allowed to eat and drink ad libitum. All the experimental procedures were performed in line with protocols approved by the Institutional Animal Care and Research Advisory Committee of Tianjin Medical University Cancer Institute and Hospital. Cell culture The human CRC cell line SW480 and HCT116, and the human embryo kidney epithelial cell line HEK293T were acquired from the cell bank of the Chinese Academy of Sciences (Shanghai, China). The human oxaliplatin‐resistant CRC cell line SW480/oxaliplatin (L‐OHP) and HCT116/L‐OHP were established via gradual exposure of the parent cells to increasing concentrations of oxaliplatin in regular cell culture conditions for the selection of resistant cells. HEK293T was cultured in DMEM (Gibco, Grand Island, NY,

Read the complete text